HKSE - Delayed Quote HKD

Simcere Pharmaceutical Group Limited (2096.HK)

5.300 +0.060 (+1.15%)
At close: April 26 at 4:08 PM GMT+8

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
NameTitlePayExercisedYear Born
Mr. Jinsheng Ren Co-Founder, Chairman & CEO 3.12M -- 1962
Mr. Yushan Wan CFO, Joint Company Secretary & Executive Director 7.48M -- 1970
Mr. Renhong Tang Ph.D. Executive Director 14.53M -- 1980
Mr. Gaobo Zhou Chief Investment Officer -- -- 1979
Mr. Quanfu Feng Vice President of Marketing -- -- 1965
Dr. Bijoyesh Mookerjee M.D. Chief Medical Officer of Oncology -- -- 1962
Mr. Danny Chen Ph.D. Senor Vice President -- -- 1968
Mr. Tong Zhu Chief Operating Officer of Simcere Zaiming -- -- 1978
Dr. Tamas Oravecz Ph.D. Senior VP & Chief Scientific Officer of U.S. -- -- --
Ms. Xi Wang VP & Executive Director -- -- 1983

Simcere Pharmaceutical Group Limited

No. 699-18, Xuanwu Road
Xuanwu District
Nanjing, 210042
China
86 25 8556 6666 https://www.simcere.com
Sector: 
Healthcare
Full Time Employees: 
7,027

Description

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets. The company also offers promotion services for pharmaceutical products. It has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize SIM0801 and other drugs in the Greater China region. In addition, the company engages in the manufacture of pharmaceutical ingredients; and property management business. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China.

Corporate Governance

Simcere Pharmaceutical Group Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Mar 21, 2024
Simcere Pharmaceutical Group Limited Earnings Call

Jun 18, 2024

Ex-Dividend Date